Table 1.
Clinical Experience with Epigenetic Therapy in Epithelial Ovarian Cancer.
| Citation | 1st Author | Year | Study Type | Regimen | # Pts | Population | Findings |
|---|---|---|---|---|---|---|---|
| HDAC Inhibitors | |||||||
| (Modesitt et al., 2008) | Modesitt | 2008 | Phase 2 | Vorinostat | 27 | Platinum-resistant | 1 PR, 9 SD, only 2 patients had PFS > 6 months |
| (Mendivil et al., 2013) | Mendivil | 2013 | Phase 2 | Vorinostat + paclitaxel/carbo | 18 | Primary therapy | 7 CR, 2 PR, 2 SD, ORR 50%. Terminated early due to GI perforation in 3 patients |
| (Matulonis et al., 2015) | Matulonis | 2015 | Phase 1 | Vorinostat + gemcitabine/carbo | 15 | 1st recurrence, platinum-sensitive | 6 PR, 1 SD. Terminated early due to hematologic toxicity |
| (Mackay et al., 2010) | Mackay | 2010 | Phase 2 | Belinostat | 32 | Platinum-resistant EOC or LMP | LMP: 1 PR, 10 SD EOC: 9 SD |
| (Dizon et al., 2012a) | Dizon | 2012 | Phase 2 | Belinostat + carbo | 27 | Platinum-resistant | ORR 7.4%. Terminated early due to lack of activity |
| (Dizon et al., 2012b) | Dizon | 2012 | Phase 1b/2 | Belinostat + paclitaxel/carbo | 35 | Recurrent EOC | 3 CR, 12 PR, ORR 43% |
| DNMT Inhibitors | |||||||
| (Fu et al., 2011) | Fu | 2011 | Phase 1 | 5AZA + carbo | 17 | Platinum-resistant | 1 CR, 3 PR, 10 SD. ORR 22% |
| (Falchook et al., 2013) | Falchook | 2013 | Phase 1 | 5AZA + VPA + carbo | 32 (10 EOC) | Platinum-resistant | 3/10 EOC patients had minor response or SD > 4 months |
| (Fang et al., 2010) | Fang | 2010 | Phase 1 | Decitabine + carbo | 9 | Platinum-resistant | 1 CR, 3 SD > 6 months |
| (Matei et al., 2012) | Matei | 2012 | Phase 2 | Decitabine + carbo | 17 | Platinum-resistant | 1 CR, 5 PR, 6 SD. 35% ORR |
| (Odunsi et al., 2014) | Odunsi | 2014 | Phase 1 | NY-ESO-1 vaccine + decitabine + PLD | 10 | Recurrent EOC | 5 SD, 1 PR |
Carbo = carboplatin; 5AZA = 5-azacytidine; VPA = valproic acid; PLD = pegylated liposomal doxorubicin; EOC = epithelial ovarian cancer; LMP = low malignant potential; CR = complete response; PR = partial response; SD = stable disease; ORR = objective response rate; PFS = progression-free survival.